[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BOE Technology Group Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100638388","phase-1-a-phase-i-trial-of-umbilical-cord-mesenchymal-stromal-cells-for-acute-ischemic-stroke-100638388",false,"NCT07628933","A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord-derived Mesenchymal Stromal Cell Injection in Patients With Acute Ischemic Stroke (AIS)","Inclusion Criteria:\n\n* Age ≥18 years, both genders included.\n* Clinical diagnosis of anterior circulation ischemic stroke, and able to receive the investigational product within 48 hours after the onset of stroke symptoms.\n* National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive), with a score of \\\u003C2 on item Ia of the NIHSS.\n* Pre-stroke modified Rankin Scale (mRS) score ≤1.\n* The participant voluntarily agrees to participate in this study, signs the informed consent form personally or via a legal guardian, and has good compliance.\n\nExclusion Criteria:\n\n* Planned or already performed thrombectomy for the current stroke.\n* Treatment with neuroprotective agents after the current stroke.\n* History of cerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after the current ischemic stroke, and judged by the investigator to be unsuitable for participation in the clinical trial.\n* Uncontrolled systemic diseases, including but not limited to: hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure ≥100 mmHg), diabetes mellitus (acute diabetic complications such as ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, or hypoglycemic coma within the past 3 months, or glycated hemoglobin \\>8.5%, or poorly controlled blood glucose \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin), liver failure (Child-Pugh Class C), severe heart failure (New York Heart Association \\[NYHA\\] Class IV), severe chronic respiratory disease.\n* Organ function meeting any one or more of the following criteria:\n\n  1. Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL, platelet count (PLT) \\\u003C100×10⁹\u002FL, hemoglobin (Hb) \\\u003C90 g\u002FL;\n  2. Aspartate aminotransferase (AST) \\>2.5× upper limit of normal (ULN) and\u002For alanine aminotransferase (ALT) \\>2.5×ULN, serum total bilirubin (TBIL) \\>1.5×ULN;\n  3. Creatinine (Cr) \\>1.5×ULN;\n  4. For patients not receiving anticoagulant or antithrombotic therapy: international normalized ratio (INR) \\>1.7 or activated partial thromboplastin time (APTT) \\>1.25×ULN; for patients receiving anticoagulant or antithrombotic therapy: INR \\>3.0 or APTT \\>1.5×ULN.\n* Diagnosis of immunodeficiency disease, or long-term use of immunosuppressants or systemic corticosteroids at high doses within a short period before screening.\n* Epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological or psychiatric disorders that, in the investigator's opinion, could affect the participant's ability to participate in the trial or interfere with study assessments.\n* Presence of autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.).\n* Inability to undergo cranial CT\u002FMRI examination for any reason (e.g., metallic implants such as cardiac pacemakers, claustrophobia, etc.).\n* Participation in another clinical trial of an investigational drug within 3 months before screening.\n* Pregnancy, breastfeeding, planned pregnancy, or inability to use effective contraceptive measures.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in this study.","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Study Methods: The trial consists of two phases, both including a placebo control.\n\nPhase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set. This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Dose escalation to the next level is permitted only after safety assessment at 28 days post-dose in the previous group.\n\nPhase Ib (multiple-dose): Based on Phase Ia results, two dose groups will be selected. The product is administered on Day 0, Day 7, and Day 14 (3 doses total). The trial remains randomized, double-blind, and placebo-controlled.",[26,27],"Acute Ischemic Stroke","AIS",[27,29],"hUC-MSCs","NOT_YET_RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":20},"2026-06-30",{"date":38,"type":20},"2029-11-30",{"name":40,"class":41},"BOE Technology Group Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100635368","phase-1-allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors-100635368","NCT07551778","Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","An Exploratory Clinical Study to Evaluate the Safety and Efficacy of Allogeneic NK Cell Injection Combined With Standard Maintenance Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Age 18-75 years, either gender\n2. Cohort 1 \\& 3: Histologically or cytologically confirmed locally advanced unresectable or metastatic non-squamous NSCLC (Stage IIIB-IV) without known actionable driver gene mutations (including but not limited to: EGFR sensitizing mutations, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, KRAS mutation)\n3. Cohort 1 \\& 3: Previously received 4-6 cycles of first-line induction therapy with PD-(L)1 inhibitor combined with pemetrexed plus platinum, with radiographic assessment of non-progressive disease (CR, PR, or SD per RECIST 1.1)\n4. Cohort 2: Histologically or cytologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma (unresectable Stage III or Stage IV per AJCC 8th edition)\n5. Cohort 2: Previously received 6-9 cycles of first-line induction therapy with cetuximab or bevacizumab combined with FOLFOX or FOLFIRI, with radiographic assessment of non-progressive disease (CR, PR, or SD per RECIST 1.1)\n6. Prior neoadjuvant\u002Fadjuvant chemotherapy allowed if disease recurrence or metastasis occurred \\>6 months after last chemotherapy dose\n7. At least one measurable lesion per RECIST 1.1 (except patients who achieved CR during induction therapy): non-lymph node lesion ≥1.0 cm in longest diameter, or lymph node lesion ≥1.5 cm in short diameter; lesions treated with local therapy (radiation or interventional) cannot be target lesions unless progression is documented\n8. Adequate bone marrow and organ function:\n\n   1. ANC ≥1.5×10⁹\u002FL; Platelet \\>90×10⁹\u002FL; Hemoglobin \\>9 g\u002FdL\n   2. Liver function: Total bilirubin \\\u003C1.5×ULN; ALT and AST \\\u003C3×ULN (\\\u003C5×ULN if liver metastases present)\n   3. Renal function: Serum creatinine ≤1.5×ULN\n   4. Coagulation: PT, APTT, INR \\\u003C1.5×ULN\n9. ECOG performance status 0-1\n10. Life expectancy ≥3 months\n11. Non-pregnant, non-lactating; women of childbearing potential must have negative serum pregnancy test within 7 days before cell infusion and agree to use reliable contraception during study and for 6 months after last infusion; men with partners of childbearing potential must agree to use reliable contraception\n12. Voluntary informed consent and able to comply with follow-up\n\nExclusion Criteria:\n\n1. Prior treatment with other cellular therapy products (DC, CIK, T cells, NK cells, CAR-T, etc.) except this product\n2. Other malignancies within 5 years before screening (completely resolved carcinoma in situ and slowly progressing malignancies as determined by investigator excluded)\n3. Symptomatic moderate to severe third-space effusion requiring therapeutic drainage\n4. Gastrointestinal perforation, fistula, or intra-abdominal abscess within 6 months\n5. Significant cardiovascular disease history including\n6. Arterial or venous thrombotic events within 6 months before enrollment (CVA, DVT, PE, etc.)\n7. Active infection (viral, bacterial, fungal) currently being treated, or any infection requiring IV antibiotics for ≥7 days within past 6 weeks, or oral antibiotics within past 1 week\n8. Active autoimmune disease or history of severe autoimmune disease requiring long-term immunosuppression\n9. Participation in other interventional clinical trials within 3 months\n10. Toxicities from prior interventions not resolved to Grade ≤2 (alopecia excluded)\n11. Untreated chronic active hepatitis B, chronic HBV carriers with HBV DNA ≥1000 copies\u002FmL; HCV antibody positive with HCV-RNA positive; HIV antibody positive; syphilis antibody positive\n12. Any other condition deemed by investigator to make subject unsuitable for study participation","75 Years",{"count":52,"type":20},20,[23,54],"PHASE2","This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally advanced or metastatic solid tumors. The study consists of three cohorts: Cohort 1 (advanced non-squamous NSCLC with NK cells + PD-(L)1 inhibitor + pemetrexed), Cohort 2 (advanced colorectal adenocarcinoma with NK cells + cetuximab\u002Fbevacizumab + capecitabine), and Cohort 3 (lymphodepletion exploration cohort with fludarabine + cyclophosph preconditioning followed by NK cells + PD-(L)1 inhibitor + pemetrexed).",[57,58,59],"NSCLC (Advanced Non-small Cell Lung Cancer)","Colorectal Cancer","Advanced Solid Tumors","2026-04-20",{"date":62,"type":34},"2026-04-27",{"date":64,"type":20},"2026-05",{"date":66,"type":20},"2029-04",{"name":40,"class":41},""]